252 related articles for article (PubMed ID: 20585937)
21. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.
de Vries F; Pouwels S; Lammers JW; Leufkens HG; Bracke M; Cooper C; van Staa TP
J Intern Med; 2007 Feb; 261(2):170-7. PubMed ID: 17241182
[TBL] [Abstract][Full Text] [Related]
22. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study.
de Vries F; Pouwels S; Bracke M; Leufkens HG; Cooper C; Lammers JW; van Staa TP
Pharmacoepidemiol Drug Saf; 2007 Jun; 16(6):612-9. PubMed ID: 16998945
[TBL] [Abstract][Full Text] [Related]
23. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
Kaye JA; Jick H
Pharmacotherapy; 2008 Aug; 28(8):951-9. PubMed ID: 18657011
[TBL] [Abstract][Full Text] [Related]
24. Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study.
Min YW; Lee YC; Kim K; Ryu S; Hong KS; Jeon HH; Kim YS; Park JH; Son HJ; Rhee PL
Korean J Intern Med; 2020 Sep; 35(5):1084-1093. PubMed ID: 31671930
[TBL] [Abstract][Full Text] [Related]
25. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model.
Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ
J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296
[TBL] [Abstract][Full Text] [Related]
26. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study.
Chiu HF; Huang YW; Chang CC; Yang CY
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1131-6. PubMed ID: 20872906
[TBL] [Abstract][Full Text] [Related]
27. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis.
Ye X; Liu H; Wu C; Qin Y; Zang J; Gao Q; Zhang X; He J
Eur J Gastroenterol Hepatol; 2011 Sep; 23(9):794-800. PubMed ID: 21701389
[TBL] [Abstract][Full Text] [Related]
28. Use of proton pump inhibitors and risk of osteoporosis-related fractures.
Targownik LE; Lix LM; Metge CJ; Prior HJ; Leung S; Leslie WD
CMAJ; 2008 Aug; 179(4):319-26. PubMed ID: 18695179
[TBL] [Abstract][Full Text] [Related]
29. Proton pump inhibitors and bone fractures?
Laine L
Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S21-6. PubMed ID: 19262543
[TBL] [Abstract][Full Text] [Related]
30. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates.
de Vries F; Cooper AL; Cockle SM; van Staa TP; Cooper C
Osteoporos Int; 2009 Dec; 20(12):1989-98. PubMed ID: 19333676
[TBL] [Abstract][Full Text] [Related]
31. Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients.
Lenihan CR; Sukumaran Nair S; Vangala C; Ramanathan V; Montez-Rath ME; Winkelmayer WC
Am J Kidney Dis; 2017 May; 69(5):595-601. PubMed ID: 27866965
[TBL] [Abstract][Full Text] [Related]
32. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study.
Torvinen-Kiiskinen S; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Hartikainen S; Taipale H
Aliment Pharmacol Ther; 2018 Apr; 47(8):1135-1142. PubMed ID: 29508411
[TBL] [Abstract][Full Text] [Related]
33. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
[TBL] [Abstract][Full Text] [Related]
34. Proton pump inhibitors and fracture risk. The HUNT study, Norway.
Hoff M; Skovlund E; Skurtveit S; Meyer HE; Langhammer A; Søgaard AJ; Syversen U; Forsmo S; Abrahamsen B; Schei B
Osteoporos Int; 2020 Jan; 31(1):109-118. PubMed ID: 31741023
[TBL] [Abstract][Full Text] [Related]
35. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study.
Adams AL; Black MH; Zhang JL; Shi JM; Jacobsen SJ
Ann Epidemiol; 2014 Apr; 24(4):286-90. PubMed ID: 24507954
[TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
37. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
Lyu B; Hansen KE; Jorgenson MR; Astor BC
Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
[TBL] [Abstract][Full Text] [Related]
38. Proton pump inhibitor use and the antifracture efficacy of alendronate.
Abrahamsen B; Eiken P; Eastell R
Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
[TBL] [Abstract][Full Text] [Related]
39. Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study.
Miyano S; Michihata N; Sada KE; Uda K; Matsui H; Fushimi K; Nangaku M; Yasunaga H
Rheumatology (Oxford); 2021 Apr; 60(4):1717-1723. PubMed ID: 33067623
[TBL] [Abstract][Full Text] [Related]
40. Proton-pump inhibitors and risk of fractures: an update meta-analysis.
Zhou B; Huang Y; Li H; Sun W; Liu J
Osteoporos Int; 2016 Jan; 27(1):339-47. PubMed ID: 26462494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
